Skip to main content
. Author manuscript; available in PMC: 2024 Sep 1.
Published in final edited form as: Ann Oncol. 2023 Jul 1;34(9):772–782. doi: 10.1016/j.annonc.2023.06.009

Figure 4. Overall survival at IA2 in the BRCA1/2 subgroup: (A) stratified analysis and (B) IPCW analysis.

Figure 4.

Figure 4.

AAP, abiraterone acetate with prednisone; CI, confidence interval; HR, hazard ratio; IA2, second interim analysis; IPCW, inverse probability censoring weighting; NIRA, niraparib; PBO, placebo. aNominal P value.